Heart failure is increasing in prevalence and is a debilitating disease with high rates of mortality and morbidity [1] . Cardiac hypertrophy is a common precursor to many forms of heart failure, whose molecular and cellular determinants remain largely unknown [2] . After 
prevent cardiac hypertrophy and heart failure. The cellular repressor of E1A-stimulated genes (CREG) is a secreted glycoprotein that has been shown to antagonize transcription activation and cellular transformation induced by the adenovirus E1A oncoprotein [8] . Recent studies showed that CREG transferring to the injured artery inhibited SMC dedifferentiation and proliferation, and reduced neointimal hyperplasia [9, 10] . Xu and colleagues [11] 
Methods and materials Materials

Antibodies for the mitogen-activated protein kinases (MAPKs) and Smads pathways were purchased from Cell Signaling Technology (Danvers, MA, USA). The anti-CREG (reactive with mouse or human) antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). [ 3 H]-Leucine and [ 3 H]-proline were purchased from Amersham. NF-B-luc,
CTGF-and COL1A2-luc report constructs were described previously [12] . [12] . 
The bicinchoninic acid (BCA) protein assay kit was purchased from Pierce (Rockford, IL, USA). All other antibodies were purchased from Santa Cruz Biotechnology. Transforming growth factor-␤1 (TGF-␤1) was purchased from R&D Systems (Minneapolis, MN, USA). Foetal calf serum (FCS) was obtained from Hyclone (Logan, UT, USA). Cell culture reagents and all other reagents were obtained from Sigma (Oakville, ON, Canada).
Animals and animal models
Quantitative real-time RT-PCR and Western blotting
Electrophoretic mobility shift assays (EMSA) and histological analysis
For EMSA, nuclear proteins were isolated as described previously [12, 13] . 
Collagen synthesis assay and reporter assays
Collagen synthesis was evaluated by measuring 3 H-proline incorporation as described previously [12] . (Fig. 1D ). (Fig. 3C) . Therefore, we chose no. 3 (Fig. 3D) . Our (Fig. 3E) .
Results
Generation of mice with cardiac-specific overexpression of CREG
The effect of CREG on cardiac hypertrophy in vivo
shCREG for the following experiments. Further studies showed that Ang II induced a significant phosphorylation of MEK and ERK1/2 that was almost completely blocked and sustained for all tested timepoints by overexpression of CREG, whereas decreased CREG levels by infection of Ad-shCREG resulted in pronounced activation of MEK and ERK1/2 in cardiac myocytes
In order to examine whether MEK-ERK1/2 signalling has a causative role in CREG-mediated inhibition of cardiac hypertrophy, further in vitro experiments were performed. As expected, decreased CREG levels led to pronounced hypertrophy induced by Ang II as assessed by [H 3 ]-leucine incorporation and surface area measurements, which was strongly blunted by treatment with ERK1/2 inhibitor U0126 (Fig. 3F). These results suggest that CREG inhibits cardiac hypertrophy through direct inhibition of MEK-ERK1/2 signalling in cardiac myocytes.
The effect of CREG on fibrosis in vivo and in vitro
Cardiac hypertrophy is associated with increased fibrosis in the myocardium, characterized by the over-production of extracellular matrix proteins [13] . (Fig. 4I) . [14, 15] . To further elucidate 
The effect of CREG on TGF-␤/Smad signalling
TGF-␤1 induces collagen synthesis via activation of a number of transcription factors, including Smads
The effect of CREG on inflammation in vivo and in vitro
Activation of inflammatory signalling pathways promotes cardiac hypertrophy and fibrosis, whereas inhibition of inflammation can attenuate these responses [16, 17] (Fig. 6A and B) . Further studies demonstrated that [18, 19] . The MAPK cascade consists of a sequence of successively acting kinases, including p38, JNKs, and ERKs and is initiated in cardiac myocytes by stress stimuli [18, 19] 
